Trials / Completed
CompletedNCT02807909
A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects
An Open-Label Single-Sequence Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-Dose Pharmacokinetics of BMS-986177 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The study is being conducted to assess the effects of co-administration of itraconazole or diltiazem, respectively, on the pharmacokinetic (PK) parameters Cmax, AUC(INF), and AUC(0-T) of BMS-986177
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986177 | |
| DRUG | Itraconazole | |
| DRUG | Diltiazem ER |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2016-06-21
- Last updated
- 2016-09-12
Source: ClinicalTrials.gov record NCT02807909. Inclusion in this directory is not an endorsement.